Stem Cell Transplant From Donors After Alpha Beta Cell Depletion in Children and Adults With T-allo10 Cells Addback
Recruiting now · Phase 1
Conditions studied: Hematologic Diseases
In brief
The purpose of this study is to determine the safety of a cell therapy, T-allo10, after αβdepleted-HSCT in the hopes that it will boost the adaptive immune reconstitution of the patient while sparing the risk of developing severe Graft-versus-Host Disease (GvHD). The primary objective of Phase 1a is to determine the recommended Phase 2 dose (RP2D) administered after infusion of αβdepleted-HSCT in children and young adults with hematologic malignancies. A Phase 1b extension will occur after dose escalation, enrolling at the RP2D for the T-allo10 cells determined in the Phase 1 portion to evaluate the safety and efficacy of infusion of T-allo10 after receipt of αβdepleted-HSCT. Additionally, Phase 1b aims to explore improvements in immune reconstitution. All participants on this study must be enrolled on another study: NCT04249830
Key facts
- Study ID
- NCT04640987
- Run by
- Porteus, Matthew, MD
- People needed
- 22
- Starts
- 2021-02-10
- Expected to finish
- 2029-03-01
- Last updated by the study team
- 2026-01-08
Who can join
Age: 0 and older, up to 45. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Lucile Packard Children's Hospital — Palo Alto, California, United States (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.